Cancer clinical trials in the region Pays de la Loire

440 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Lung cancer #NCT06868277 #2024-517780-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
11 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT07205822 #2025-521904-23-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
5 recruiting sites
AstraZeneca
Phase 3 Lung cancer #NCT06472245 #2023-509340-10-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
29 recruiting sites
OSE Immunotherapeutics
Phase 3 Prostate cancer #NCT07164443
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 3 Thymus cancer #NCT05918302 #2022-502154-13-00
Required histologic types
Other
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2
8 recruiting sites
Phase 3 Sarcoma and GIST #NCT04307277 #2024-515384-62-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery
Required sarcoma grades
Grade 1 Grade 2 Grade 3
20 recruiting sites
Institut Claudius Regaud
Phase 3 Colon cancer Rectal cancer #NCT02885753
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
83 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 3 Acute leukemia #NCT04307576 #2022-501050-11-01
Required histologic types
Acute lymphoblastic leukemia (ALL)
Required histologic sub types
T-cell (T-ALL) B-cell (B-ALL)
Required genetic anomalies
MYC
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
28 recruiting sites
Karolinska University Hospital
Phase 3 Lung cancer #NCT04790253
Required histologic types
SCLC (Small Cell Lung Cancer)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
17 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Lymphoma #NCT06191744 #2023-506906-38-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
8 recruiting sites
Genmab